Neurology Psychiatric News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neurology psychiatric. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neurology Psychiatric Today - Breaking & Trending Today

Neurovalens gets FDA nod for neurostimulator to treat anxiety

Neurovalens Ltd recently received U.S. FDA clearance for its Modius Stress device, a neurostimulator that treats people suffering from generalized anxiety disorder (GAD). It also closed a £2.1 million (US$2.65 million) funding round and is planning to raise up to $50 million in a series B fundraising round to be launched later this year. ....

Neurovalens Ltd , Modius Stress , Bioworld Medtech , Electromedical Products International Inc , Fisher Wallace Laboratories , Generalized Anxiety Disorder , Neurovalens Ltd , Neuro Fitness Llc , Neurology Psychiatric , Series B ,

Quest adds pTau217 to Alzheimer's test portfolio

Quest Diagnostics Inc. expanded its Alzheimer’s disease (AD) portfolio with a blood-based biomarker test for phosphorylated tau 217 (pTau217). The test joins the company’s plasma tests for p-tau181, beta-amyloid 42/40 ratio and ApoE genetic risk as well as several cerebrospinal fluid tests for Alzheimer’s. ....

Quest Diagnostics Inc , Quest Diagnostics , Helmholtz Diabetes Center , Cancer Induced Cachexia , Penx Acip , Bioworld Medtech , Quest Diagnostics Inc , Alzheimers Disease , Ptau 217 , P Tau217 , Laboratory Corporation Of America Holdings Inc , Quanterix Corp , Meso Scale Diagnostics Llc , Neurocode Usa Inc , Neurology Psychiatric ,

Cerevel undersell? Bombshell Parkinson's phase III with tavapadon

Cerevel Therapeutics Inc.’s positive results from the long-shot pivotal phase III Tempo-3 trial with tavapadon – the first D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease – added gravy to the $8.7 billion takeover by Abbvie Inc., disclosed late last year. The buyout’s centerpiece was the late-stage asset emraclidine, a positive allosteric modulator of the muscarinic M4 receptor, touted as a potential best-in-class, next-generation antipsychotic for schizophrenia, which strikes more than 5 million people in the G7 (U.S., France, Germany, Italy, Spain, U.K. and Japan). ....

Cerevel Therapeutics Inc , Abbvie Inc , Cerevel Therapeutics , Cerevel Therapeutics Inc , Parkinsons Disease , Neurology Psychiatric , Abbvie Inc , D1 D5 Receptor Partial Agonist , Adjunctive Therapy , Small Molecule ,

Neuropeptide released by pain neurons promotes wound healing by interacting with immune system

Wound healing is a highly specialized dynamic process for the repair of damaged/injured tissues through an intricate mechanism. Any failure in the normal wound healing process results in abnormal scar formation, and a chronic state which is more susceptible to infections. Researchers from Monash University in Australia and Osaka University in Japan have demonstrated that the removal of a specific subtype of sensory neurons containing the Nav1.8+ ion channel significantly impairs skin wound repair and muscle regeneration following injury. ....

South Australia , Monash University , Osaka University , Bioworld Science , Calcitonin Gene Related Peptide , Wound Healing , Neurology Psychiatric ,

Aging, and aging well, gives clues for dementia drug discovery

Ironically, the first person to be diagnosed with what is now Alzheimer’s disease was missing its major risk factor. When she first began showing symptoms of dementia in 1901, Auguste Deter was not particularly old. Despite Deter’s case, aging is the largest risk factor for developing Alzheimer’s, by a large margin. But “geroscience has not been translated into drugs for Alzheimer’s disease,” Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief scientific officer, told BioWorld. “We’re just starting to see that cross-fertilization now.” This first article of a three-part BioWorld series on Alzheimer’s disease looks at how a group of researchers, as well as some startups, are trying to approach Alzheimer’s via an aging lens. ....

Howard Fillit , Auguste Deter , Alzheimer Drug Discovery Foundation , Drug Discovery Foundation , Bioworld Science , Alzheimers Disease , Neuroage Therapeutics Inc , Neurology Psychiatric ,